MedTrace Logo

Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

NCT05345561 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14390

Last updated 2026-03-06

No results posted yet for this study

Summary

A prospective, non-interventional, natural history study to assess the occurrence of higher FNAIT risk across a broad population of different racial and ethnic characteristics and the occurrence of HPA-1a alloimmunization in these women.

Conditions

  • Fetal and Neonatal Alloimmune Thrombocytopenia

Interventions

OTHER

Clinical data collection

Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.

Sponsors & Collaborators

  • Rallybio

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2025-01-31
Completion
2025-10-10

Countries

  • United States
  • Canada
  • Germany
  • Netherlands
  • Norway
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05345561 on ClinicalTrials.gov